{
    "clinical_study": {
        "@rank": "36985", 
        "arm_group": {
            "arm_group_label": "[14C]Copanlisib", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "The study aims to provide understanding of the relative relevance of the different excretion\n      pathways of Copanlisib in humans, as well as to characterize its metabolite profile."
        }, 
        "brief_title": "Copanlisib Mass Balance Study", 
        "completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Healthy Volunteers", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Healthy male subject\n\n          -  Age: 45 to 65 years\n\n          -  Body weight greater or equal to 60 kg and body mass index (BMI): above/equal 18 and\n             below/equal 30 kg/m\u00b2\n\n        Exclusion Criteria:\n\n          -  Regular use of medicines\n\n          -  Known recent (last 2 years) abuse of recreational drugs, suspicion of drug or alcohol\n             abuse, or positive results of the drug and alcohol screen tests at screening or\n             baseline\n\n          -  Use of strong inhibitors of cytochrome P450 (CYP)3A4, as well as use of St John's\n             Wort or strong inducers of CYP3A4 prohibited from 14 days before the administration\n             of study drug until discharge from the clinic\n\n          -  Smoking\n\n          -  Average intake of more than 24 units of alcohol per week; Regular daily consumption\n             of more than 1 L of methylxanthine-containing beverages\n\n          -  Any condition, which may result in longer than usual retention of urine or feces in\n             the body, such as pronounced (less than one defecation in 2 days) constipation or\n             symptomatic prostatic hypertrophy.\n\n          -  Participation in another mass balance study with a radiation burden > 0.1 mSv in the\n             period of 1 year before screening"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "65 Years", 
            "minimum_age": "45 Years"
        }, 
        "enrollment": {
            "#text": "6", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "April 17, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02119221", 
            "org_study_id": "16353", 
            "secondary_id": "2013-002544-90"
        }, 
        "intervention": {
            "arm_group_label": "[14C]Copanlisib", 
            "description": "Intravenous infusion of 12 mg copanlisib labeled with 2.76 MBq (75 \u03bcCi) of [14C]", 
            "intervention_name": "Copanlisib (BAY80-6946)", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "April 17, 2014", 
        "link": [
            {
                "description": "Click here and search for drug information provided by the FDA.", 
                "url": "http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm"
            }, 
            {
                "description": "Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.", 
                "url": "http://www.fda.gov/medwatch/safety.htm"
            }
        ], 
        "location": {
            "facility": {
                "address": {
                    "city": "Zuidlaren", 
                    "country": "Netherlands", 
                    "zip": "9471 GP"
                }
            }
        }, 
        "location_countries": {
            "country": "Netherlands"
        }, 
        "number_of_arms": "1", 
        "official_title": "Single Center, Open-label, Non-randomized, Non-placebo-controlled Study to Investigate the Metabolism, Excretion Pattern, Mass Balance, Safety, Tolerability and Pharmacokinetics After Single Intravenous Administration of 12 mg [14C]Copanlisib (BAY 80-6946) in Healthy Male Subjects", 
        "overall_official": {
            "affiliation": "Bayer", 
            "last_name": "Bayer Study Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "April 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Pharmacokinetics of copanlisib in plasma by maximum concentration (Cmax)", 
                "safety_issue": "No", 
                "time_frame": "Multiple time points up to 336 hours"
            }, 
            {
                "measure": "Pharmacokinetics of copanlisib in plasma by area under the measured matrix concentration versus time curve from the first time point (t=0) extrapolated to infinity (AUC)", 
                "safety_issue": "No", 
                "time_frame": "Multiple time points up to 336 hours"
            }, 
            {
                "measure": "Pharmacokinetics of copanlisib in plasma by area under the measured matrix concentration versus time curve to the last data point above the lower limit of quantitation (AUC(0-tlast))", 
                "safety_issue": "No", 
                "time_frame": "Multiple time points up to 336 hours"
            }, 
            {
                "measure": "Pharmacokinetics of total radioactivity in plasma by Cmax", 
                "safety_issue": "No", 
                "time_frame": "Multiple time points up to 336 hours"
            }, 
            {
                "measure": "Pharmacokinetics of total radioactivity in plasma by AUC", 
                "safety_issue": "No", 
                "time_frame": "Multiple time points up to 336 hours"
            }, 
            {
                "measure": "Pharmacokinetics of total radioactivity in plasma by AUC(0-tlast)", 
                "safety_issue": "No", 
                "time_frame": "Multiple time points up to 336 hours"
            }, 
            {
                "measure": "Pharmacokinetics of total radioactivity in whole blood by Cmax", 
                "safety_issue": "No", 
                "time_frame": "Multiple time points up to 336 hours"
            }, 
            {
                "measure": "Pharmacokinetics of total radioactivity in whole blood by AUC", 
                "safety_issue": "No", 
                "time_frame": "Multiple time points up to 336 hours"
            }, 
            {
                "measure": "Pharmacokinetics of total radioactivity in whole blood by AUC(0-tlast)", 
                "safety_issue": "No", 
                "time_frame": "Multiple time points up to 336 hours"
            }, 
            {
                "measure": "Radioactivity excreted in urine as a percentage of the dose (AE,ur)", 
                "safety_issue": "No", 
                "time_frame": "Multiple time points up to 336 hours"
            }, 
            {
                "measure": "Radioactivity excreted in feces as a percentage of the dose (AE,fec)", 
                "safety_issue": "No", 
                "time_frame": "Multiple time points up to 336 hours"
            }, 
            {
                "measure": "Metabolite profile in plasma", 
                "safety_issue": "No", 
                "time_frame": "Multiple time points up to 336 hours"
            }, 
            {
                "measure": "Metabolite profile in urine", 
                "safety_issue": "No", 
                "time_frame": "Multiple time points up to 336 hours"
            }, 
            {
                "measure": "Metabolite profile in feces", 
                "safety_issue": "No", 
                "time_frame": "Multiple time points up to 336 hours"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02119221"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Number of participants with adverse events as a measure of safety and tolerability", 
            "safety_issue": "Yes", 
            "time_frame": "Until 30 days after study drug administration"
        }, 
        "source": "Bayer", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Bayer", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2014", 
        "study_design": "Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}